Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis.
The immunohistochemical distribution of tenascin (TN), fibronectin (FN), and laminin (LN) was investigated in 56 human gliomas (8 astrocytomas, 15 anaplastic astrocytomas, and 33 glioblastomas) with regards to the histological degree of malignancy and the degree of tumor cell differentiation evaluated by the staining of glial fibrillary acidic protein (GFAP). In 8 anaplastic astrocytomas and 28 glioblastomas, TN was predominantly immunolocalized in the basement membrane zone of the proliferating tumor vessels; sections of all astrocytomas were negative for TN staining. FN was localized in the basement membrane zone of the vessels in all astrocytomas, 12 anaplastic astrocytomas, and 22 glioblastomas. In 7 anaplastic astrocytomas and 19 glioblastomas, both TN and FN were expressed to various degrees in the tumor vessels. However, most of the TN-positive vessels did not express FN, and most of the FN-positive vessels were negative for TN staining. Furthermore, in 6 anaplastic astrocytomas and 12 glioblastomas, either TN or FN, but not both, were expressed in any area on serial sections. Most of the tumor cells around TN-positive, FN-negative tumor vessels did not express GFAP. On the other hand, GFAP was present in most tumor cells around TN-negative, FN-positive vessels. LN was detected in all vascular and pial-glial basement membrane zone of the tissues examined. These findings indicate that the degree of histological malignancy and the degree of cell dedifferentiation of human gliomas correlate well with the expression of TN, but are inversely correlated with the expression of FN.(ABSTRACT TRUNCATED AT 250 WORDS)
Higuchi
M
M
Department of Neurosurgery, Osaka University Medical School, Japan.
Ohnishi
T
T
Arita
N
N
Hiraga
S
S
Hayakawa
T
T
D000911:Antibodies, Monoclonal / Q000276:immunology; D001254:Astrocytoma / Q000473:pathology; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D015816:Cell Adhesion Molecules, Neuronal / Q000096:biosynthesis* / Q000276:immunology; D002454:Cell Differentiation; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis* / Q000276:immunology; D005353:Fibronectins / Q000096:biosynthesis / Q000276:immunology; D005904:Glial Fibrillary Acidic Protein / Q000276:immunology / Q000378:metabolism; D005909:Glioblastoma / Q000473:pathology; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D007797:Laminin / Q000096:biosynthesis / Q000276:immunology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000473:pathology*; D016612:Paraffin Embedding; D019063:Tenascin
D000911:Antibodies, Monoclonal; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D005904:Glial Fibrillary Acidic Protein; D007797:Laminin; D009363:Neoplasm Proteins; D019063:Tenascin